We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NIC:ASXNickel Industries Limited Analysis

Data as of 2026-03-12 - not real-time

A$0.92

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Nickel Industries is trading well above its 20‑day SMA (≈0.97) and comfortably above the 50‑day SMA (≈0.95), keeping the price in a bullish zone despite a bearish MACD crossover and a modest RSI around the mid‑40s. Volatility remains elevated (≈48% over 30 days) and beta is slightly above 1, indicating heightened price swings relative to the market. The stock sits near the identified support level of ~0.84 and below the resistance around 1.06, with current volume trending downwards, suggesting limited short‑term buying pressure.
On the fundamentals side, the company posted a revenue decline of roughly 9% and a negative profit margin, while the trailing EPS is still in the red. However, forward EPS is projected positive and the forward P/E of about 6.9 signals cheap valuation. A strong dividend yield near 4% is offset by a payout ratio exceeding 100%, raising questions about sustainability. Recent news of a “major sales quota boost” and stronger margins for 2026 adds a growth catalyst, and analysts collectively rate the stock as a strong buy with an upside potential of roughly 28%.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support with bearish MACD signal
  • Decreasing volume and high short‑term volatility
  • Neutral RSI suggesting limited upside momentum

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward earnings growth and low forward P/E
  • Material sales quota increase improving margins
  • Attractive dividend yield despite payout concerns

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Long‑term demand for nickel in electric‑vehicle supply chains
  • Undervalued book value relative to price
  • Potential upside to analyst target price around 1.10‑1.18

Key Metrics & Analysis

Financial Health

Revenue Growth-9.10%
Profit Margin-3.46%
P/E Ratio6.9
ROE-1.64%
ROA1.78%
Debt/Equity49.87
P/B Ratio1.4
Op. Cash FlowA$187.9M
Free Cash FlowA$54.2M

Technical Analysis

TrendBullish
RSI45.4
SupportA$0.84
ResistanceA$1.06
MA 20A$0.97
MA 50A$0.95
MA 200A$0.78
MACDBearish
VolumeDecreasing
Fear & Greed Index75.88

Valuation

Target PriceA$1.18
Upside/Downside27.90%
GradeUndervalued
TypeBlend
Dividend Yield3.94%

Risk Assessment

Beta1.08
Volatility48.40%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.